Table 2). There was a significant difference between the corresponding serum HER-2 levels taken before the development of metastatic disease (range 4–1729, mean 162, median 22.3 μg/L) and serum HER-2 levels in patients without metastasis (range 5–18, mean 10, median 10.1 μg/L) (p=0.0003). In our previous work [10], we found a good correlation between increased serum HER-2 values and the development of metastatic disease in tissue-positive patients. This evidence concerns the gene ERBB2 and metastatic neoplasm.